Keytruda® (pembrolizumab) – Expanded indication
July 27, 2021 - Merck announced the FDA approval of Keytruda (pembrolizumab), for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
Top